PMID- 25703419
OWN - NLM
STAT- MEDLINE
DCOM- 20160212
LR  - 20220309
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 184
DP  - 2015 Apr 1
TI  - Use, efficacy and safety of prasugrel in patients with ST segment elevation 
      myocardial infarction scheduled for primary percutaneous coronary intervention in 
      clinical practice. Results of the prospective ATACS-registry.
PG  - 122-127
LID - S0167-5273(15)00074-1 [pii]
LID - 10.1016/j.ijcard.2015.01.047 [doi]
AB  - BACKGROUND: Prasugrel compared to clopidogrel has been shown to improve outcome 
      in patients with ST elevation myocardial infarction (STEMI) in the TRITON-TIMI 38 
      trial. Little is known about the use, efficacy and safety of prasugrel in 
      patients with STEMI in clinical practice. METHODS: We conducted a prospective 
      registry including patients with STEMI scheduled for primary percutaneous 
      coronary intervention (PCI). Between October 2009 and February 2013 a total of 
      3291 patients with STEMI receiving a loading dose of either clopidogrel or 
      prasugrel were included in this analysis. RESULTS: Prasugrel was predominantly 
      used in patients <75 years, body weight >60 kg and those without prior stroke. 
      In-hospital mortality was numerically lower in the prasugrel group (1.7% vs. 
      4.4%), as well as non-fatal reinfarction (0.2% vs. 0.5%), non-fatal stroke (0.1% 
      vs. 0.3%) and major cardiac and cerebrovascular events (MACCE) (2.1% vs. 5.2%), 
      while there was no difference in major bleeding complications (0.8% vs. 0.9%). In 
      the multivariate analysis the MACCE-rate tended to be lower in prasugrel treated 
      patients (odds ratio 0.71, 95% confidence intervals 0.42-1.08) but bleeding-rates 
      tended to be higher. CONCLUSIONS: In this real life experience in patients with 
      STEMI scheduled for primary PCI, prasugrel was almost exclusively used in the 
      label-recommended patient population and tended to be more effective but 
      associated with more bleedings compared to clopidogrel. These results support the 
      findings in the STEMI population in the randomized TRITON-TIMI 38 study.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany; Institut fur 
      Herzinfarktforschung Ludwigshafen, Germany. Electronic address: 
      Uwe.Zeymer@t-online.de.
FAU - Hochadel, Matthias
AU  - Hochadel M
AD  - Institut fur Herzinfarktforschung Ludwigshafen, Germany.
FAU - Lauer, Bernward
AU  - Lauer B
AD  - Zentrallinik Bad Berka, Germany.
FAU - Kaul, Norbert
AU  - Kaul N
AD  - Stiftungsklinikum Mittelrhein, Koblenz, Germany.
FAU - Wohrle, Jochen
AU  - Wohrle J
AD  - Universitatsklinikum Ulm, Ulm, Germany.
FAU - Andresen, Dietrich
AU  - Andresen D
AD  - Vivantes Klinikum am Urban, Berlin, Germany.
FAU - Schwimmbeck, Peter
AU  - Schwimmbeck P
AD  - Klinikum Leverkusen, Leverkusen, Germany.
FAU - Solzbach, Ulrich
AU  - Solzbach U
AD  - Ostalb-Klinikum Aalen, Aalen, Germany.
FAU - Thiele, Holger
AU  - Thiele H
AD  - Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Germany.
FAU - Gitt, Anselm
AU  - Gitt A
AD  - Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany; Institut fur 
      Herzinfarktforschung Ludwigshafen, Germany.
FAU - Diller, Frank
AU  - Diller F
AD  - Institut fur Herzinfarktforschung Ludwigshafen, Germany.
FAU - Zahn, Ralf
AU  - Zahn R
AD  - Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150126
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
SB  - IM
MH  - Acute Coronary Syndrome/diagnosis/drug therapy/mortality
MH  - Aged
MH  - Aged, 80 and over
MH  - *Appointments and Schedules
MH  - Female
MH  - Hemorrhage/chemically induced/diagnosis/mortality
MH  - Hospital Mortality/trends
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/mortality
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prasugrel Hydrochloride/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - *Registries
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Clopidogrel
OT  - Percutaneous coronary intervention
OT  - Prasugrel
OT  - ST elevation myocardial infarction
EDAT- 2015/02/24 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/02/24 06:00
PHST- 2014/06/23 00:00 [received]
PHST- 2014/11/02 00:00 [revised]
PHST- 2015/01/25 00:00 [accepted]
PHST- 2015/02/24 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - S0167-5273(15)00074-1 [pii]
AID - 10.1016/j.ijcard.2015.01.047 [doi]
PST - ppublish
SO  - Int J Cardiol. 2015 Apr 1;184:122-127. doi: 10.1016/j.ijcard.2015.01.047. Epub 
      2015 Jan 26.